The Total Approach in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia (LUTS/BPH) Management: Introduction and Conclusions

European Urology, Supplement

Volumn 2, Issue 7, 2003, Pages 1-5

  Chapple, Christopher R ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Bladder outlet obstruction; Disease management; Disease progression; Lower urinary tract symptoms; Morbidity; Quality of life; Symptoms

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; INDORAMIN; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; BLADDER NECK STENOSIS; CARDIOTOXICITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT PLANNING; URINARY TRACT OBSTRUCTION;

EID: 0242556621     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2003.09.001     Document Type: Conference Paper

References (15)

1. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-9.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
3. Hunter DJW, Berra-Unamuno A, Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol 1996;155:1965-70.
4. Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MCJM, for the Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 2002;42:323-8.
5. Logie JW, Clifford GM, Farmer RDT, Meesen BPW. Lower urinary tract symptoms suggestive of benign prostatic obstruction-Triumph: the role of general practice databases. Eur Urol 2001 39(Suppl 3): 42-7.
6. Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJMCH, Porru D, Thüroff JW, and the International Continence Society 'Benign Prostatic Hyperplasia' Study Group. The International Continence Society 'Benign Prostatic Hyperplasia' Study: the bothersomeness of urinary symptoms. J Urol 1997; 157: 885-9.
7. Lieber MM, Jacobsen DJ, Giman CJ, Roberts RO, Rhodes T, Jacobsen SJ. Incidence of lower urinary tract symptom progression in community-dwelling men: 9-year follow-up of the Olmsted County study of urinary symptoms and health status among men. J Urol 2003;169(Suppl):366 [Abstract 1369].
8. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Lieber MM. Acute urinary retention in community-dwelling men: 9-year follow-up of the Olmsted County study of urinary symptoms and health status among men. J Urol 2003;169(Suppl):365 [Abstract 1364].
9. McConnell JD. The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 2002;167(Suppl 4):265 [Abstract 1042].
10. Barry M, Roehrborn C. Benign prostatic hyperplasia. Clinical Evidence 2002;7:775-87.
11. Michel MC, Goepel M. Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice. Eur Urol 2000;38(Suppl 1):40-7.
12. Jiménez-Cruz F. Identifying patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003;2(7):6-12 (this issue).
13. Michel MC. Protecting bladder function and reducing disease progression. Eur Urol Suppl 2003;2(7):13-18 (this issue).
14. Berges R. Impact of therapy used in practice on lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) disease progression. Eur Urol Suppl 2003;2(7):19-24 (this issue).
15. O'Leary MP. Achieving the total approach in lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) management. Eur Urol Suppl 2003;2(7):25-33 (this issue).